UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2015
Commission File Number: 001-33623
WuXi
PharmaTech (Cayman) Inc.
288 Fute Zhong Road, Waigaoqiao Free Trade Zone
Shanghai 200131
People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ¨ No x
If “Yes” is
marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82- N/A
WuXi PharmaTech (Cayman) Inc.
Form 6-K
TABLE OF CONTENTS
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WuXi PharmaTech (Cayman) Inc. |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Edward Hu |
|
|
|
|
|
|
Name: |
|
Edward Hu |
|
|
|
|
|
|
Title: |
|
Chief Financial Officer |
|
|
|
|
| Date: August 17, 2015 |
|
|
|
|
|
|
3
Exhibit 99.1
WuXi PharmaTech Announces Second-Quarter 2015 Results
SHANGHAI, August 13, 2015 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (“WuXi”) (NYSE: WX), a leading open-access R&D capability and
technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the second quarter of 2015.
Second-Quarter 2015 Highlights
| • |
|
Net Revenues Increased 18.8% Year Over Year to $194.1 Million |
| • |
|
Net Revenues for Laboratory Services Grew 17.9% Year Over Year to $123.5 Million |
| • |
|
Net Revenues for Small-Molecule Manufacturing Services Increased 10.0% Year Over Year to $45.9 Million |
| • |
|
Net Revenues for Biologics Services Grew 48.4% Year Over Year to $18.3 Million |
| • |
|
Net Revenues for New Businesses and Other Grew 42.8% Year Over Year to $6.4 Million |
| • |
|
GAAP Diluted Earnings Per ADS Declined 35.9% Year Over Year to $0.26 |
| • |
|
Non-GAAP Diluted Earnings Per ADS Decreased 21.6% Year Over Year to $0.38 |
| • |
|
Company Reconfirms Full-Year 2015 Revenue Guidance of $790-$800 Million, Withdraws Full-Year 2015 Diluted EPS Guidance Due to Uncertainties Regarding Currency Exchange-Rate Volatility and Costs Associated with Several
Transactions Under Consideration |
Management Comment
“WuXi had excellent year-over-year revenue growth of 18.8% in the second quarter, meeting the company’s expectations,” said Dr. Ge Li,
Chairman and CEO. “That revenue growth was again broad-based, with double-digit growth from each of the four segments of the business. Revenue growth in our small-molecule manufacturing businesses was slightly lower than expected due to the
timing of product deliveries, but this is not expected to impact the full-year performance of this business. The revenue performance of our biologics business exceeded expectations. This overall performance gives us confidence to reconfirm our
full-year 2015 revenue guidance of $790-$800 million.
“The quarter was also characterized by significant year-over-year declines in margins and
diluted EPS because of sharply increased levels of investment in new businesses,” Dr. Li continued. “WuXi today is two groups of businesses—strong core businesses, and promising, but very challenging, new businesses. Our core
businesses are performing well, generating solid revenue and operating income growth. But we also see many compelling investment opportunities in new businesses, such as in genomics / bioinformatics, e-commerce, and China healthcare initiatives,
opportunities that we are choosing to seize during this period of strength to drive longterm growth. To date, these new businesses are developing more slowly than we had anticipated.
“As many of you know, the RMB depreciated significantly versus the US dollar earlier this week, and this depreciation could result in significant
mark-to-market losses and realized losses on foreign-exchange forward contracts in the third quarter and full year,” Dr. Li concluded. “In addition, WuXi is considering several transactions that in comparison to historical results
could further reduce margins and diluted EPS in full-year 2015 and beyond. Therefore, because of uncertainties regarding these circumstances, we are withdrawing our GAAP and non-GAAP diluted EPS financial guidance for full-year 2015.”
4
Second-Quarter 2015 GAAP Results
Second-quarter 2015 net revenues increased 18.8% year over year to $194.1 million. Laboratory Services revenue grew 17.9%, driven by our comprehensive and
integrated drug discovery and development services. Revenue growth of 10.0% in Small-Molecule Manufacturing Services resulted from strong demand in both research manufacturing and commercial manufacturing, slightly reduced by the timing of
deliveries of specific projects. Biologics Services revenue increased 48.4% from strong growth in both development and manufacturing. Revenue growth of 42.8% in New Businesses and Other related mainly to the significant revenue increase of clinical
site management services in China, offset by slower than expected growth in the genomics / bioinformatics business.
Second-quarter 2015 GAAP gross profit
increased 8.4% year over year to $66.7 million due to 18.8% revenue growth, partially offset by increased labor costs in China and investments in new businesses. Gross margin decreased year over year to 34.4% from 37.7%. Gross margin in Laboratory
Services decreased year over year to 37.0% from 40.9% due to increased labor costs in China and investments in new businesses. Gross margin in Small-Molecule Manufacturing Services increased year over year to 36.6% from 31.8% because of changes in
business mix and higher capacity utilization. The decrease in gross margin in Biologics Services year over year to 25.0% from 34.5% was caused by investments in biomanufacturing, which is in an early stage of its revenue ramp-up. Gross margin in New
Businesses and Other decreased year over year to (5.8%) from 25.3% mainly as a result of investments in genomics and bioinformatics.
Second-quarter
2015 GAAP operating income decreased 39.1% year over year to $17.1 million mainly due to investments in new businesses, including increased selling and marketing, general and administrative, and research and development expenses and transaction
expenses related to the proposed privatization, partially offset by the 8.4% increase in gross profit. Operating margin declined to 8.8% from 17.1% due to these increased operating expenses.
Second-quarter 2015 GAAP net income decreased 33.7% year over year to $19.4 million mainly due to the 39.1% year-over-year decrease in operating income, an
adverse change in realized gains on settled foreign-exchange forward contracts (gains of $0.2 million in the second quarter of 2015 compared to gains of $1.6 million in the second quarter of 2014), larger equity-method investment losses from our
joint ventures with PRA and MedImmune and other equity-method investments, losses of $1.2 million from writing off an investment in a portfolio company by our venture fund and lower gains on the sale of investments by the corporate venture fund
(gains of $1.1 million in the second quarter of 2015 compared to gains of $2.2 million in the second quarter of 2014), and higher interest expense due to higher loan balances needed to support increased investment, partially offset by a favorable
change of $5.8 million in mark-to-market gains and losses on foreign-exchange forward contracts (gains of $3.3 million in the second quarter of 2015 compared to losses of $2.5 million in the second quarter of 2014).
Second-quarter 2015 GAAP net income attributable to WuXi shareholders decreased 35.7% year over year to $18.9 million mainly due to the 33.7% year-over-year
decrease in net income and net income attributable to non-controlling interests of $0.6 million in 2015.
Second-quarter 2015 GAAP diluted earnings per
ADS attributable to WuXi shareholders decreased 35.9% year over year to $0.26 due to the 35.7% decrease in net income attributable to WuXi shareholders and a higher number of outstanding ADSs as a result of share issuances relating to the XenoBiotic
Laboratories acquisition and vesting of restricted stock units, partially offset by the impact of share purchases in 2014. Second-quarter 2015 GAAP comprehensive income attributable to WuXi shareholders decreased 21.2% year over year to $19.0
million mainly due to the 35.7% decrease in net income and an unfavorable change in unrealized losses on available-for-sale securities, partially offset by favorable changes in currency translation adjustments and cash flow hedges.
5
Second-Quarter 2015 Non-GAAP Results
Non-GAAP financial results exclude the impact of share-based compensation expenses and the amortization of acquired intangible assets and the associated
deferred tax impact.
Second-quarter 2015 non-GAAP gross profit increased 11.6% year over year to $70.5 million due to 18.8% revenue growth, offset by
increased labor costs in China and investments in new businesses. Non-GAAP gross margin decreased year over year to 36.3% from 38.7% for the same reasons.
Second-quarter 2015 non-GAAP operating income decreased 22.3% year over year to $26.4 million due to investments in new businesses, including increased
selling and marketing, general and administrative, and research and development expenses and transaction expenses related to the proposed privatization, partially offset by the 11.6% increase in non-GAAP gross profit.
Non-GAAP operating margin decreased to 13.6% from 20.8% due to higher operating expenses.
Second-quarter 2015
non-GAAP net income decreased 19.4% year over year to $28.4 million mainly due to the 22.3% year-over-year decrease in operating income, an adverse change in realized gains on settled foreign-exchange forward contracts (gains of $0.2 million in the
second quarter of 2015 compared to gains of $1.6 million in the second quarter of 2014), larger equity-method investment losses from our joint ventures with PRA and MedImmune and other equity-method investments, losses of $1.2 million from writing
off an investment in a portfolio company by our venture fund and lower gains on the sale of investments by the corporate venture fund (gains of $1.1 million in the second quarter of 2015 compared to gains of $2.2 million in the second quarter of
2014), and higher interest expense due to higher loan balances needed to support higher investment, partially offset by a favorable change of $5.8 million in mark-to-market gains and losses on foreign-exchange forward contracts (gains of $3.3
million in the second quarter of 2015 compared to losses of $2.5 million in the second quarter of 2014).
Second-quarter 2015 non-GAAP net income
attributable to WuXi shareholders decreased 21.3% year over year to $27.7 million mainly due to the 19.4% year-over-year decrease in net income and net income attributable to noncontrolling interests of $0.6 million in 2015.
Second-quarter 2015 non-GAAP diluted earnings per ADS attributable to WuXi shareholders decreased 21.6% year over year to $0.38 due to the 21.3% decrease in
net income attributable to WuXi shareholders and a higher number of outstanding ADSs as a result of share issuances relating to the XenoBiotic Laboratories acquisition and vesting of restricted stock units, partially offset by the impact of share
purchases in 2014.
Full-Year 2015 Financial Guidance
WuXi PharmaTech reconfirms full-year 2015 revenue guidance of $790-$800 million. The company withdraws its full-year 2015 guidance for GAAP and non-GAAP
diluted EPS because of uncertainties regarding currency exchange-rate volatility and potential significant costs associated with several transactions under consideration. The rapid depreciation of the RMB against the U.S. dollar could result in
significant mark-to-market losses and realized losses on foreign-exchange forward contracts.
6
WUXI PHARMATECH (CAYMAN) INC.
UNAUDITED CONSOLIDATED BALANCE SHEETS
(in thousands of U.S. dollars, except ordinary share and par value data)
|
|
|
|
|
|
|
|
|
| |
|
June 30,
2015 |
|
|
December 31,
2014 |
|
| Assets: |
|
|
|
|
|
|
|
|
| Current assets: |
|
|
|
|
|
|
|
|
| Cash and cash equivalents |
|
|
253,530 |
|
|
|
211,456 |
|
| Restricted cash |
|
|
710 |
|
|
|
793 |
|
| Short-term investments |
|
|
204,651 |
|
|
|
223,533 |
|
| Accounts receivable, net |
|
|
179,014 |
|
|
|
162,942 |
|
| Amounts due from related parties |
|
|
6,855 |
|
|
|
4,397 |
|
| Inventories |
|
|
61,405 |
|
|
|
48,546 |
|
| Prepaid expenses and other current assets |
|
|
37,724 |
|
|
|
31,990 |
|
|
|
|
|
|
|
|
|
|
| Total current assets |
|
|
743,889 |
|
|
|
683,657 |
|
|
|
|
|
|
|
|
|
|
| Non-current assets: |
|
|
|
|
|
|
|
|
| Goodwill * |
|
|
89,780 |
|
|
|
53,619 |
|
| Property, plant and equipment, net |
|
|
395,562 |
|
|
|
351,688 |
|
| Long-term investments |
|
|
103,299 |
|
|
|
49,037 |
|
| Intangible assets, net * |
|
|
51,489 |
|
|
|
23,020 |
|
| Land use rights |
|
|
13,975 |
|
|
|
14,120 |
|
| Deferred tax assets |
|
|
2,158 |
|
|
|
1,417 |
|
| Other non-current assets |
|
|
5,827 |
|
|
|
5,068 |
|
|
|
|
|
|
|
|
|
|
| Total non-current assets |
|
|
662,090 |
|
|
|
497,969 |
|
|
|
|
|
|
|
|
|
|
| Total assets |
|
|
1,405,979 |
|
|
|
1,181,626 |
|
|
|
|
|
|
|
|
|
|
| Liabilities and equity: |
|
|
|
|
|
|
|
|
| Current liabilities: |
|
|
|
|
|
|
|
|
| Short-term and current portion of long-term debt |
|
|
112,407 |
|
|
|
199,719 |
|
| Accounts payable |
|
|
67,904 |
|
|
|
58,466 |
|
| Amounts due to related parties |
|
|
419 |
|
|
|
275 |
|
| Accrued expenses |
|
|
44,484 |
|
|
|
43,454 |
|
| Deferred revenue |
|
|
30,804 |
|
|
|
27,669 |
|
| Advanced subsidies |
|
|
12,322 |
|
|
|
12,106 |
|
| Other taxes payable |
|
|
6,051 |
|
|
|
2,299 |
|
| Other current liabilities |
|
|
24,037 |
|
|
|
29,787 |
|
|
|
|
|
|
|
|
|
|
| Total current liabilities |
|
|
298,428 |
|
|
|
373,775 |
|
|
|
|
|
|
|
|
|
|
| Non-current liabilities: |
|
|
|
|
|
|
|
|
| Long-term debt, excluding current portion |
|
|
228,867 |
|
|
|
13,987 |
|
| Advanced subsidies |
|
|
3,057 |
|
|
|
2,286 |
|
| Other non-current liabilities * |
|
|
23,192 |
|
|
|
13,724 |
|
|
|
|
|
|
|
|
|
|
| Total non-current liabilities |
|
|
255,116 |
|
|
|
29,997 |
|
|
|
|
|
|
|
|
|
|
| Total liabilities |
|
|
553,544 |
|
|
|
403,772 |
|
|
|
|
|
|
|
|
|
|
| Equity: |
|
|
|
|
|
|
|
|
| Ordinary shares ($0.02 par value, 5,002,550,000 authorized, 567,444,208 and 561,159,373 issued and outstanding as of June 30, 2015
and December 31, 2014, respectively) |
|
|
11,349 |
|
|
|
11,223 |
|
| Additional paid-in capital |
|
|
326,642 |
|
|
|
295,308 |
|
| Retained earnings |
|
|
451,985 |
|
|
|
415,329 |
|
| Accumulated other comprehensive income |
|
|
54,371 |
|
|
|
55,994 |
|
|
|
|
|
|
|
|
|
|
| Equity attributable to shareholders of WuXi |
|
|
844,347 |
|
|
|
777,854 |
|
|
|
|
|
|
|
|
|
|
| Non-controlling interests |
|
|
8,088 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
| Total shareholders’ equity |
|
|
852,435 |
|
|
|
777,854 |
|
|
|
|
|
|
|
|
|
|
| Total liabilities and equity |
|
|
1,405,979 |
|
|
|
1,181,626 |
|
|
|
|
|
|
|
|
|
|
| * |
A preliminary allocation of the purchase price of NextCODE Health, LLC., to the assets acquired and liabilities assumed was made based on available information and incorporating management’s current estimates.
The Company is currently finalizing the valuation of the assets acquired and liabilities assumed. The final allocation of the purchase price may differ from this preliminary allocation. |
7
WUXI PHARMATECH (CAYMAN) INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands of U.S. dollars, except ADS data and per ADS data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
| |
|
2015 |
|
|
2014 |
|
|
% Change |
|
|
2015 |
|
|
2014 |
|
|
% Change |
|
| Net revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Laboratory services |
|
|
123,467 |
|
|
|
104,765 |
|
|
|
17.9 |
% |
|
|
237,753 |
|
|
|
199,528 |
|
|
|
19.2 |
% |
| Small-molecule manufacturing services |
|
|
45,893 |
|
|
|
41,720 |
|
|
|
10.0 |
% |
|
|
91,442 |
|
|
|
81,410 |
|
|
|
12.3 |
% |
| Biologics services |
|
|
18,347 |
|
|
|
12,365 |
|
|
|
48.4 |
% |
|
|
32,760 |
|
|
|
20,618 |
|
|
|
58.9 |
% |
| New businesses and other |
|
|
6,431 |
|
|
|
4,504 |
|
|
|
42.8 |
% |
|
|
12,227 |
|
|
|
8,515 |
|
|
|
43.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total net revenues |
|
|
194,138 |
|
|
|
163,354 |
|
|
|
18.8 |
% |
|
|
374,182 |
|
|
|
310,071 |
|
|
|
20.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Laboratory services |
|
|
(77,780 |
) |
|
|
(61,893 |
) |
|
|
25.7 |
% |
|
|
(148,401 |
) |
|
|
(118,802 |
) |
|
|
24.9 |
% |
| Small-molecule manufacturing services |
|
|
(29,095 |
) |
|
|
(28,458 |
) |
|
|
2.2 |
% |
|
|
(57,853 |
) |
|
|
(55,125 |
) |
|
|
4.9 |
% |
| Biologics services |
|
|
(13,756 |
) |
|
|
(8,102 |
) |
|
|
69.8 |
% |
|
|
(26,105 |
) |
|
|
(14,718 |
) |
|
|
77.4 |
% |
| New businesses and other |
|
|
(6,804 |
) |
|
|
(3,363 |
) |
|
|
102.3 |
% |
|
|
(12,307 |
) |
|
|
(6,261 |
) |
|
|
96.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total cost of revenues |
|
|
(127,435 |
) |
|
|
(101,816 |
) |
|
|
25.2 |
% |
|
|
(244,666 |
) |
|
|
(194,906 |
) |
|
|
25.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross profit: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Laboratory services |
|
|
45,687 |
|
|
|
42,872 |
|
|
|
6.6 |
% |
|
|
89,352 |
|
|
|
80,726 |
|
|
|
10.7 |
% |
| Small-molecule manufacturing services |
|
|
16,798 |
|
|
|
13,262 |
|
|
|
26.7 |
% |
|
|
33,589 |
|
|
|
26,285 |
|
|
|
27.8 |
% |
| Biologics services |
|
|
4,591 |
|
|
|
4,263 |
|
|
|
7.7 |
% |
|
|
6,655 |
|
|
|
5,900 |
|
|
|
12.8 |
% |
| New businesses and other |
|
|
(373 |
) |
|
|
1,141 |
|
|
|
NA |
|
|
|
(80 |
) |
|
|
2,254 |
|
|
|
NA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total gross profit |
|
|
66,703 |
|
|
|
61,538 |
|
|
|
8.4 |
% |
|
|
129,516 |
|
|
|
115,165 |
|
|
|
12.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Selling and marketing expenses |
|
|
(7,052 |
) |
|
|
(5,042 |
) |
|
|
39.9 |
% |
|
|
(13,688 |
) |
|
|
(9,542 |
) |
|
|
43.5 |
% |
| General and administrative expenses |
|
|
(34,910 |
) |
|
|
(23,662 |
) |
|
|
47.5 |
% |
|
|
(67,730 |
) |
|
|
(45,000 |
) |
|
|
50.5 |
% |
| Research and development expenses |
|
|
(7,686 |
) |
|
|
(4,831 |
) |
|
|
59.1 |
% |
|
|
(14,052 |
) |
|
|
(9,209 |
) |
|
|
52.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total operating expenses |
|
|
(49,648 |
) |
|
|
(33,535 |
) |
|
|
48.0 |
% |
|
|
(95,470 |
) |
|
|
(63,751 |
) |
|
|
49.8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating income |
|
|
17,055 |
|
|
|
28,003 |
|
|
|
(39.1 |
%) |
|
|
34,046 |
|
|
|
51,414 |
|
|
|
(33.8 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other income (expenses), net: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss from equity-method investments |
|
|
(1,734 |
) |
|
|
(810 |
) |
|
|
114.1 |
% |
|
|
(3,316 |
) |
|
|
(1,643 |
) |
|
|
101.8 |
% |
| Other income (expenses), net |
|
|
4,600 |
|
|
|
4,620 |
|
|
|
(0.4 |
%) |
|
|
8,435 |
|
|
|
(820 |
) |
|
|
NA |
|
| Interest income (expenses), net |
|
|
2,950 |
|
|
|
4,198 |
|
|
|
(29.7 |
%) |
|
|
5,736 |
|
|
|
8,749 |
|
|
|
(34.4 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total other income (expenses), net |
|
|
5,816 |
|
|
|
8,008 |
|
|
|
(27.4 |
%) |
|
|
10,855 |
|
|
|
6,286 |
|
|
|
72.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Income before income taxes |
|
|
22,871 |
|
|
|
36,011 |
|
|
|
(36.5 |
%) |
|
|
44,901 |
|
|
|
57,700 |
|
|
|
(22.2 |
%) |
| Income tax expense |
|
|
(3,422 |
) |
|
|
(6,675 |
) |
|
|
(48.7 |
%) |
|
|
(7,668 |
) |
|
|
(10,542 |
) |
|
|
(27.3 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net income |
|
|
19,449 |
|
|
|
29,336 |
|
|
|
(33.7 |
%) |
|
|
37,233 |
|
|
|
47,158 |
|
|
|
(21.0 |
%) |
| Less: Net income attributable to non-controlling interests |
|
|
(577 |
) |
|
|
— |
|
|
|
NA |
|
|
|
(577 |
) |
|
|
— |
|
|
|
NA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net income attributable to WuXi shareholders |
|
|
18,872 |
|
|
|
29,336 |
|
|
|
(35.7 |
%) |
|
|
36,656 |
|
|
|
47,158 |
|
|
|
(22.3 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Currency translation adjustments |
|
|
(275 |
) |
|
|
(5,324 |
) |
|
|
(94.8 |
%) |
|
|
(747 |
) |
|
|
(11,158 |
) |
|
|
(93.3 |
%) |
| Unrealized gains (losses) on available-for-sale securities |
|
|
(1,357 |
) |
|
|
115 |
|
|
|
NA |
|
|
|
(2,749 |
) |
|
|
(75 |
) |
|
|
|
* |
| Cash flow hedges, net of tax |
|
|
1,806 |
|
|
|
— |
|
|
|
NA |
|
|
|
1,874 |
|
|
|
— |
|
|
|
NA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other comprehensive income (loss) |
|
|
174 |
|
|
|
(5,209 |
) |
|
|
NA |
|
|
|
(1,622 |
) |
|
|
(11,233 |
) |
|
|
(85.6 |
%) |
| Less: Other comprehensive income attributable to non-controlling interests |
|
|
(5 |
) |
|
|
— |
|
|
|
NA |
|
|
|
(5 |
) |
|
|
— |
|
|
|
NA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other comprehensive income (loss) att. to WuXi shareholders |
|
|
169 |
|
|
|
(5,209 |
) |
|
|
NA |
|
|
|
(1,627 |
) |
|
|
(11,233 |
) |
|
|
(85.5 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Comprehensive income att. to WuXi shareholders |
|
|
19,041 |
|
|
|
24,127 |
|
|
|
(21.2 |
%) |
|
|
35,029 |
|
|
|
35,925 |
|
|
|
(2.5 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Basic net earnings per ADS att. to WuXi shareholders |
|
|
0.27 |
|
|
|
0.42 |
|
|
|
(35.9 |
%) |
|
|
0.52 |
|
|
|
0.66 |
|
|
|
(21.7 |
%) |
| Diluted net earnings per ADS att. to WuXi shareholders |
|
|
0.26 |
|
|
|
0.41 |
|
|
|
(35.9 |
%) |
|
|
0.51 |
|
|
|
0.65 |
|
|
|
(21.7 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted average ADS outstanding—basic |
|
|
70,891,036 |
|
|
|
70,671,831 |
|
|
|
0.3 |
% |
|
|
70,611,042 |
|
|
|
71,149,836 |
|
|
|
(0.8 |
%) |
| Weighted average ADS outstanding—diluted |
|
|
72,376,462 |
|
|
|
72,073,199 |
|
|
|
0.4 |
% |
|
|
72,182,247 |
|
|
|
72,735,360 |
|
|
|
(0.8 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8
WUXI PHARMATECH (CAYMAN) INC.
RECONCILIATION OF GAAP TO NON-GAAP
(in thousands of U.S. dollars, except ADS data and per ADS data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
| |
|
2015 |
|
|
2014 |
|
|
% Change |
|
|
2015 |
|
|
2014 |
|
|
% Change |
|
|
|
|
|
|
|
|
| GAAP gross profit |
|
|
66,703 |
|
|
|
61,538 |
|
|
|
8.4 |
% |
|
|
129,516 |
|
|
|
115,165 |
|
|
|
12.5 |
% |
| GAAP gross margin |
|
|
34.4 |
% |
|
|
37.7 |
% |
|
|
|
|
|
|
34.6 |
% |
|
|
37.1 |
% |
|
|
|
|
| Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based compensation |
|
|
2,617 |
|
|
|
1,621 |
|
|
|
61.4 |
% |
|
|
4,201 |
|
|
|
2,687 |
|
|
|
56.3 |
% |
| Amortization of acquired intangible assets |
|
|
1,208 |
|
|
|
48 |
|
|
|
|
* |
|
|
2,606 |
|
|
|
97 |
|
|
|
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-GAAP gross profit |
|
|
70,528 |
|
|
|
63,207 |
|
|
|
11.6 |
% |
|
|
136,323 |
|
|
|
117,949 |
|
|
|
15.6 |
% |
| Non-GAAP gross margin |
|
|
36.3 |
% |
|
|
38.7 |
% |
|
|
|
|
|
|
36.4 |
% |
|
|
38.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GAAP operating income |
|
|
17,055 |
|
|
|
28,003 |
|
|
|
(39.1 |
%) |
|
|
34,046 |
|
|
|
51,414 |
|
|
|
(33.8 |
%) |
| GAAP operating margin |
|
|
8.8 |
% |
|
|
17.1 |
% |
|
|
|
|
|
|
9.1 |
% |
|
|
16.6 |
% |
|
|
|
|
| Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based compensation |
|
|
8,103 |
|
|
|
5,873 |
|
|
|
38.0 |
% |
|
|
14,987 |
|
|
|
10,286 |
|
|
|
45.7 |
% |
| Amortization of acquired intangible assets |
|
|
1,208 |
|
|
|
48 |
|
|
|
|
* |
|
|
2,606 |
|
|
|
97 |
|
|
|
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-GAAP operating income |
|
|
26,366 |
|
|
|
33,924 |
|
|
|
(22.3 |
%) |
|
|
51,639 |
|
|
|
61,797 |
|
|
|
(16.4 |
%) |
| Non-GAAP operating margin |
|
|
13.6 |
% |
|
|
20.8 |
% |
|
|
|
|
|
|
13.8 |
% |
|
|
19.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GAAP net income |
|
|
19,449 |
|
|
|
29,336 |
|
|
|
(33.7 |
%) |
|
|
37,233 |
|
|
|
47,158 |
|
|
|
(21.0 |
%) |
| GAAP net margin |
|
|
10.0 |
% |
|
|
18.0 |
% |
|
|
|
|
|
|
10.0 |
% |
|
|
15.2 |
% |
|
|
|
|
| Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based compensation |
|
|
8,103 |
|
|
|
5,873 |
|
|
|
38.0 |
% |
|
|
14,987 |
|
|
|
10,286 |
|
|
|
45.7 |
% |
| Amortization of acquired intangible assets |
|
|
1,208 |
|
|
|
48 |
|
|
|
|
* |
|
|
2,606 |
|
|
|
97 |
|
|
|
|
* |
| Deferred tax impact related to acquired intangible assets |
|
|
(369 |
) |
|
|
(16 |
) |
|
|
|
* |
|
|
(815 |
) |
|
|
(33 |
) |
|
|
|
* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-GAAP net income |
|
|
28,391 |
|
|
|
35,241 |
|
|
|
(19.4 |
%) |
|
|
54,011 |
|
|
|
57,508 |
|
|
|
(6.1 |
%) |
| Non-GAAP net margin |
|
|
14.6 |
% |
|
|
21.6 |
% |
|
|
|
|
|
|
14.4 |
% |
|
|
18.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
| Less: Net income attributable to non-controlling interests |
|
|
(651 |
) |
|
|
— |
|
|
|
NA |
|
|
|
(651 |
) |
|
|
— |
|
|
|
NA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net Income attributable to WuXi shareholders of ADS (Non-GAAP): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Basic |
|
|
27,740 |
|
|
|
35,241 |
|
|
|
(21.3 |
%) |
|
|
53,360 |
|
|
|
57,508 |
|
|
|
(7.2 |
%) |
| Diluted |
|
|
27,740 |
|
|
|
35,241 |
|
|
|
(21.3 |
%) |
|
|
53,360 |
|
|
|
57,508 |
|
|
|
(7.2 |
%) |
|
|
|
|
|
|
|
| Basic earnings per ADS (Non-GAAP) attributable to WuXi shareholders |
|
|
0.39 |
|
|
|
0.50 |
|
|
|
(21.5 |
%) |
|
|
0.76 |
|
|
|
0.81 |
|
|
|
(6.5 |
%) |
| Diluted earnings per ADS (Non-GAAP) attributable to WuXi shareholders |
|
|
0.38 |
|
|
|
0.49 |
|
|
|
(21.6 |
%) |
|
|
0.74 |
|
|
|
0.79 |
|
|
|
(6.5 |
%) |
|
|
|
|
|
|
|
| Weighted average ADS outstanding – basic (Non-GAAP) |
|
|
70,891,036 |
|
|
|
70,671,831 |
|
|
|
0.3 |
% |
|
|
70,611,042 |
|
|
|
71,149,836 |
|
|
|
(0.8 |
%) |
| Weighted average ADS outstanding – diluted (Non-GAAP) |
|
|
72,376,462 |
|
|
|
72,073,199 |
|
|
|
0.4 |
% |
|
|
72,182,247 |
|
|
|
72,735,360 |
|
|
|
(0.8 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9
Conference Call
WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on
August 14, 2015, to discuss its second-quarter 2015 financial results and future prospects. The conference call may be accessed by calling:
|
|
|
| China |
|
4001 200 539 |
| Hong Kong |
|
800 905 927 |
| Singapore |
|
800 616 3222 |
| United Kingdom |
|
0800 015 9725 |
| United States |
|
1855 298 3404 |
| United States—New York (toll) |
|
+1 631 5142 526 |
| Other countries (toll) |
|
+65 6823 2299 |
| Conference ID |
|
2278500 |
A telephone replay will be available two hours after the call’s completion at:
|
|
|
| China |
|
4001 842 240 |
| Hong Kong |
|
800 966 697 |
| Singapore |
|
800 616 2127 |
| United Kingdom |
|
0800 169 7301 |
| United States |
|
1866 846 0868 |
| Conference ID |
|
2278500 |
A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech’s
website at http://www.wuxiapptec.com.
About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device
industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of services throughout the drug and medical device R&D process. WuXi is also
building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech’s services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and
medical device R&D. WuXi PharmaTech’s operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com.
Forward-Looking Statements
This press release contains
“forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead are predictions about future events. Examples of forward-looking
statements in this press release include statements about expected full-year 2015 revenues, costs associated with several transactions under consideration and the related negative impact on gross margins and earnings per share (EPS), expected
drivers of our future growth, and our planned investments in small-molecule manufacturing, biologics, new businesses and other areas and expected market opportunities and trends and related benefits of those investments. Although we believe that our
predictions are reasonable, future events are inherently uncertain, and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, our ability to control our
costs and sustain revenue growth, to realize the anticipated benefits of our investments, to protect our clients’ intellectual property, to compete effectively, and to complete the expansion of our small-molecule manufacturing facilities in
Changzhou and other manufacturing facilities and potential co-development and acquisition activities. Additional information about these and other relevant risks can be found in our Annual Report on Form 20-F
for the year ended December 31, 2014. The forward-looking statements in this press release speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by law.
10
Use of Non-GAAP Financial Measures
We have provided the second-quarter 2014 and 2015 gross profit, gross margin, operating income, operating margin, net income, net margin, and diluted earnings
per ADS on a non-GAAP basis, which excludes share-based compensation expenses and the amortization and deferred tax impact of acquired intangible assets. The non-GAAP financial measures used in this press release are useful for understanding and
assessing underlying business performance and operating trends, and we believe that management and investors benefit from referring to these non-GAAP financial measures in assessing our financial performance and liquidity and when planning and
forecasting future periods. We expect to continue to provide such non-GAAP financial measures on a quarterly basis using a consistent method. You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or
as being comparable to results reported or forecasted by other companies.
Statement Regarding Unaudited Financial Information
The financial information in this press release is unaudited and subject to adjustments. Adjustments to the financial statements may be identified when our
annual financial statements are prepared and audit work is performed for the year-end audit, which could result in significant differences from this unaudited financial information.
For more information, please contact:
Ronald Aldridge
(for investors)
LaVoieHealthScience
Tel: +1-617-374-8800 x
109
Email: ron_aldridge@wuxiapptec.com
raldridge@lavoiehealthscience.com
Aaron Shi (for the
media)
Director of Corporate Communications
Tel:
+86-21-5046-4362
Email: aaron_shi@wuxiapptec.com
11